Hyloris Pharmaceuticals (LTS:0AB6) Dividend Payout Ratio: 0.00 (As of Dec. 2025)


LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
64 GF Score
Price €4.49
GF Value €9.47
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Dividend Payout Ratio?

Hyloris Pharmaceuticals LTS:0AB6 +0.22% 64 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 64/100 and a GF Value™ of €9.47 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 134 Biotechnology companies, Hyloris Pharmaceuticals ranks worse than 746267.91% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Hyloris Pharmaceuticals's Dividend Payout Ratio for the months ended in Dec. 2025 was 0.00.

The historical rank and industry rank for Hyloris Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:


LTS:0AB6's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-07-05), the Dividend Yield % of Hyloris Pharmaceuticals is 0.00%.

Hyloris Pharmaceuticals's Dividends per Share for the months ended in Dec. 2025 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Hyloris Pharmaceuticals (LTS:0AB6) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Hyloris Pharmaceuticals Dividend Payout Ratio Related Terms


Hyloris Pharmaceuticals Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Dividend Payout Ratio Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0AB6 vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Dividend Payout Ratio falls into.


LTS:0AB6
64GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Hyloris Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -0.271
=N/A

Hyloris Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.14
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 134 companies in the Biotechnology industry.
Is Hyloris Pharmaceuticals' Dividend Payout Ratio too high?
Hyloris Pharmaceuticals' current Dividend Payout Ratio is 0.00. Based on the distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #999999 out of 134 companies for Dividend Payout Ratio. This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.47, compared to a current price of €4.49 — trading 52.6% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Hyloris Pharmaceuticals' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.49 is trading 52.6% below its estimated GF Value™ of €9.47. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • Dividend Payout Ratio: 0.00
  • GF Value™: €9.47 vs. price of €4.49 (52.6% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
64GF Score

Get the complete analysis for LTS:0AB6

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.49
Price
€9.47
GF Value